SG10202107808SA - Chimeric antigen receptors against axl or ror2 and methods of use thereof - Google Patents

Chimeric antigen receptors against axl or ror2 and methods of use thereof

Info

Publication number
SG10202107808SA
SG10202107808SA SG10202107808SA SG10202107808SA SG10202107808SA SG 10202107808S A SG10202107808S A SG 10202107808SA SG 10202107808S A SG10202107808S A SG 10202107808SA SG 10202107808S A SG10202107808S A SG 10202107808SA SG 10202107808S A SG10202107808S A SG 10202107808SA
Authority
SG
Singapore
Prior art keywords
ror2
methods
chimeric antigen
antigen receptors
receptors against
Prior art date
Application number
SG10202107808SA
Inventor
Gregory Ian Frost
James Joseph Onuffer
Original Assignee
F1 Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F1 Oncology Inc filed Critical F1 Oncology Inc
Publication of SG10202107808SA publication Critical patent/SG10202107808SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10202107808SA 2017-01-18 2018-01-17 Chimeric antigen receptors against axl or ror2 and methods of use thereof SG10202107808SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447898P 2017-01-18 2017-01-18
US201762467059P 2017-03-03 2017-03-03
US201762530193P 2017-07-08 2017-07-08

Publications (1)

Publication Number Publication Date
SG10202107808SA true SG10202107808SA (en) 2021-08-30

Family

ID=61157332

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202107808SA SG10202107808SA (en) 2017-01-18 2018-01-17 Chimeric antigen receptors against axl or ror2 and methods of use thereof
SG11201906468TA SG11201906468TA (en) 2017-01-18 2018-01-17 Chimeric antigen receptors against axl or ror2 and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201906468TA SG11201906468TA (en) 2017-01-18 2018-01-17 Chimeric antigen receptors against axl or ror2 and methods of use thereof

Country Status (13)

Country Link
US (1) US20190367621A1 (en)
EP (1) EP3571229A1 (en)
JP (2) JP7280827B2 (en)
KR (1) KR20190130559A (en)
CN (1) CN110177808A (en)
AU (1) AU2018211081A1 (en)
BR (1) BR112019014615A2 (en)
CA (1) CA3049674A1 (en)
IL (1) IL267902A (en)
MX (1) MX2019008503A (en)
SG (2) SG10202107808SA (en)
TW (1) TW201831505A (en)
WO (1) WO2018136570A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170260261A1 (en) 2014-08-28 2017-09-14 Bioatla, Llc Conditionally Active Chimeric Antigen Receptors for Modified T-Cells
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
WO2020047527A2 (en) * 2018-09-02 2020-03-05 F1 Bioventures, Llc Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
LT3455261T (en) * 2016-05-13 2022-11-10 Bioatla, Inc. Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
AU2019334864A1 (en) * 2018-09-07 2021-03-11 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified T-cells
CN111378039B (en) * 2018-12-29 2021-08-24 深圳大学 Antibody for treating malignant tumor and application thereof
CN111378040B (en) * 2018-12-29 2021-08-10 深圳大学 Antibody for detecting multiple malignant tumor cells and application thereof
WO2020143506A1 (en) * 2019-01-08 2020-07-16 深圳大学 Detection of malignant tumor cells antibodies and uses thereof
EP3715368A1 (en) * 2019-03-28 2020-09-30 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors, vectors coding for such receptors and their use in the modification of t cells
CN114269777A (en) * 2019-04-26 2022-04-01 北卡罗来纳大学教堂山分校 Chimeric antigen receptor constructs and their use in CAR-T cells
CN110317277A (en) * 2019-07-10 2019-10-11 杭州普科亭生物医药有限公司 Chimeric antigen receptor and its application
CN112500492B (en) * 2019-09-13 2023-08-04 中国科学院分子细胞科学卓越创新中心 Chimeric antigen receptor and application thereof
US20230111159A1 (en) * 2020-03-05 2023-04-13 Exuma Biotech Corp Methods and compositions for the delivery of modified lymphocyte aggregates
CN114075548B (en) * 2020-08-13 2023-11-21 广州医科大学附属第二医院 AXL-targeted CAR-T cell, and preparation method and application thereof
CN115125272B (en) * 2021-03-29 2024-04-19 复旦大学 CAR-T therapeutic vector and construction method and application thereof
CN116102658A (en) * 2021-11-09 2023-05-12 四川大学华西医院 Preparation and application of chimeric antigen receptor immune cells constructed based on GAS6

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
TW197439B (en) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
JP3534749B2 (en) 1991-08-20 2004-06-07 アメリカ合衆国 Adenovirus-mediated gene transfer into the gastrointestinal tract
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
AU3140093A (en) 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
JPH08500973A (en) 1992-05-21 1996-02-06 ザ ペン ステイト リサーチ ファウンデーション Taxus, related taxanes and yew cultures as raw materials for other novel anti-cancer / anti-viral compounds
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696461B1 (en) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa New derivatives of taxol analogs, their preparation and compositions containing them.
FR2696458B1 (en) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Process for the preparation of taxane derivatives.
FR2696463B1 (en) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Process for obtaining 10-deacetyl baccatin III.
FR2696462B1 (en) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Process for obtaining 10-deacetyl baccatin III.
FR2696464B1 (en) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa New esterification process for baccatin III and 10-deacetyl baccatin III.
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
ES2249761T3 (en) 1993-06-24 2006-04-01 Advec Inc. ADENOVIRUS VECTORS FOR GENE THERAPY.
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
CN1263864C (en) 1993-10-25 2006-07-12 坎吉公司 Recombinant adenoviral vector and methods of use
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
KR100445103B1 (en) 1994-12-09 2004-12-04 임페리얼 컬리지 이노베이션스 리미티드 identification
US5821263A (en) 1996-08-26 1998-10-13 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
WO1998022451A1 (en) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
CA2294606A1 (en) 1997-06-20 1998-12-30 Baker Norton Pharmaceuticals, Inc. Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (en) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd New taxane derivative
AU741433B2 (en) 1997-10-08 2001-11-29 Bio Research Corporation Of Yokohama Taxoid derivatives and process for producing the same
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
EP2918605A1 (en) 2007-11-12 2015-09-16 U3 Pharma GmbH Axl antibodies
US9175091B2 (en) 2007-11-15 2015-11-03 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
CN106008707A (en) 2009-03-09 2016-10-12 生物蛋白有限公司 Mirac proteins
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
HUE044461T2 (en) 2009-11-03 2019-10-28 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION
WO2011159980A1 (en) 2010-06-18 2011-12-22 Genentech, Inc. Anti-axl antibodies and methods of use
WO2012175692A1 (en) 2011-06-22 2012-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
EP2800975A4 (en) 2012-01-03 2015-12-09 Univ Leland Stanford Junior Analysis and targeting of ror2 in cancer
US20170260261A1 (en) 2014-08-28 2017-09-14 Bioatla, Llc Conditionally Active Chimeric Antigen Receptors for Modified T-Cells
US11111288B2 (en) * 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
US11673957B2 (en) * 2015-03-10 2023-06-13 Eureka Therapeutics, Inc. Anti-ROR2 antibodies
ES2690420T3 (en) * 2015-05-28 2018-11-20 Universität Zu Köln Anti-cough chimeric antigen receptor and its use
MX2018012418A (en) * 2016-04-15 2019-07-10 Bioatla Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof.
MX2019002199A (en) * 2016-08-31 2019-05-16 Bioatla Llc Conditionally active polypeptides and methods of generating them.

Also Published As

Publication number Publication date
JP2020503885A (en) 2020-02-06
JP2023052397A (en) 2023-04-11
JP7280827B2 (en) 2023-05-24
US20190367621A1 (en) 2019-12-05
MX2019008503A (en) 2019-09-13
CN110177808A (en) 2019-08-27
SG11201906468TA (en) 2019-08-27
BR112019014615A2 (en) 2020-06-02
WO2018136570A9 (en) 2018-10-04
WO2018136570A1 (en) 2018-07-26
TW201831505A (en) 2018-09-01
IL267902A (en) 2019-09-26
KR20190130559A (en) 2019-11-22
AU2018211081A1 (en) 2019-07-18
EP3571229A1 (en) 2019-11-27
CA3049674A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
IL267902A (en) Chimeric antigen receptors against axl or ror2 and methods of use thereof
IL275619A (en) Enhanced chimeric antigen receptors and uses thereof
IL276731A (en) Anti-cd73 antibodies and methods of use thereof
IL262041A (en) Chimeric receptors and methods of use thereof
LT3618863T (en) Anti-tigit antibodies and methods of use thereof
ZA201906730B (en) Anti-trem2 antibodies and methods of use thereof
HK1249405A1 (en) Anti-dll3 chimeric antigen receptors and methods of use
IL272274A (en) B7-h4 antibodies and methods of use thereof
IL255336A0 (en) Chimeric antigen receptors and methods of their use
EP3658163A4 (en) Enhanced chimeric antigen receptors and use thereof
IL278821A (en) Anti-sirpa antibodies and methods of use thereof
IL270214A (en) Anti-sortilin antibodies and methods of use thereof
IL265438A (en) Chimeric antigen receptors and compositions and methods of use thereof
IL277212A (en) Anti-klk5 antibodies and methods of use
IL268568A (en) Trailshort antibody and methods of use
IL274221A (en) Anti-apoc3 antibodies and methods of use thereof
IL279227A (en) Anti-siglec-7 antibodies and methods of use thereof
ZA202002144B (en) Antibodies and methods of use
IL273538A (en) Anti-trkb monoclonal antibodies and methods of use